After selling failed NASH drug to Ipsen, French startup nabs a liver disease player in small buyout – Endpoints News

The following Q&A has been edited for length and clarity.

John Carroll:

I’m joined by Jean-Charles Soria, the senior vice president oncology therapeutic area head for Amgen, Priti Hegde, the chief scientific officer for Foundation Medicine, Antoine Yver, the chairman of development for Centessa, Jeff Legos, executive vice president, global head of oncology for Novartis, and Jack West, associate professor, vice president of Network Strategy for City of Hope Comprehensive Cancer Center. I would like to thank all of you for turning out here today. I know you’ve all been very busy, and you’ve all been watching what’s been going on at ESMO, whether you’re here or watching it remotely.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.


Leave a Comment

Your email address will not be published.